Table 6.

Drug response related to CD146 expression in renal cancer cell lines.

Gene symbol	Compound	p-value	Correlation	Compound status	Target or activity of compound
CD146	gemcitabine	<0.000	-0.071	approved	inhibitor of DNA replication; inhibitor of ribonucleotide reductase, thymidylate synthetase, and cytidine monophosphate (UMP-CMP) kinase
	ML162	0.001	-0.703	probe	selectively kills engineered cells expressing mutant HRAS
	topotecan	0.002	-0.645	approved	inhibitor of topoisomerase I
	SB-225002	0.003	-0.633	probe	inhibitor of chemokine receptor 2
	SN-38	0.008	-0.572	probe	metabolite of irinotecan; inhibitor of topoisomerase I
	fluorouracil	0.010	-0.559	approved	pyrimidine analog; inhibitor of thymidylate synthase
	CR-1-31B	0.016	-0.530	probe	silvestrol analog; inhibits translation by modulating the eIF4F complex
	daporinad	0.025	-0.498	experimental	inhibitor of nicotinamide phosphoribosyltransferase
	GSK525762A	0.030	-0.485	probe	inhibitor of bromodomain (BRD) and extra-C terminal domain (BET) proteins
	BRD4132	0.031	-0.482	probe	screening hit
	clofarabine	0.032	-0.480	approved	inducer of DNA damage
	SNX-2112	0.033	-0.478	probe	inhibitor of HSP90alpha and HSP90beta
	WP1130	0.035	-0.474	probe	inhibitor of the deubiquitinase activity of USP9X, USP5, USP14, and UCH37
	I-BET151	0.035	-0.474	probe	inhibitor of bromodomain (BRD) and extra-C terminal domain (BET) proteins
	brivanib	0.038	-0.467	experimental	inhibitor of VEGFR 1/2
	serdemetan	0.040	-0.462	experimental	inhibitor of MDM2
	obatoclax	0.043	-0.456	experimental	inhibitor of MCL1, BCL2, and BCL-xL
	etoposide	0.046	-0.451	approved	inhibitor of topoisomerase II
	BIBR-1532	0.049	-0.446	probe	inhibitor of telomerase reverse transcriptase
	quizartinib	0.012	0.548	experimental	inhibitor of VEGFR3
	GSK1059615	0.027	0.495	experimental	inhibitor of PI3K and mTOR kinase activity
	BRD-K92856060	0.027	0.494	probe	screening hit
	AC55649	0.048	0.447	probe	agonist of retinoic acid receptor beta